Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Article Oncology

The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1

Hongzhong Li et al.

Summary: Antihistamines can improve survival in cancer patients by reversing T cell dysfunction through modulation of histamine receptor H1 (HRH1), thereby enhancing immunotherapy responses.

CANCER CELL (2022)

添加到收藏夹

Review Oncology

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

A. Filippone et al.

Summary: The PD-1/PD-L1 signaling pathway plays a crucial role in the progression of brain tumors and immune evasion, making it highly important in cancer immunotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma

Joseph J. Zhao et al.

Summary: By reconstructing Kaplan-Meier plots of PD-L1 CPS subgroups, this study found no significant benefit in adding immune checkpoint inhibitors to chemotherapy for low PD-L1-expressing gastroesophageal adenocarcinoma tumors.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

David M. O'Malley et al.

Summary: This phase II trial evaluated the efficacy of dual treatment with balstilimab and zalifrelimab in patients with recurrent and/or metastatic cervical cancer. The results showed promising and durable clinical activity, with favorable tolerability, in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Caicun Zhou et al.

Summary: The GEMSTONE-302 trial showed that sugemalimab plus chemotherapy significantly improved progression-free survival in previously untreated squamous and non-squamous metastatic NSCLC patients compared to placebo plus chemotherapy, regardless of PD-L1 expression. These findings have important implications for the first-line treatment of squamous and non-squamous metastatic NSCLC.

LANCET ONCOLOGY (2022)

添加到收藏夹

Correction Biochemistry & Molecular Biology

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (vol 27, pg 1536, 2021)

Hai-Qiang Mai et al.

NATURE MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Y. Doki et al.

Summary: In patients with advanced esophageal squamous-cell carcinoma, both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone, with no new safety signals identified.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Zhi Qi et al.

Summary: Combining intermittent PI3K inhibition with immune checkpoint therapy can overcome tumor intrinsic immunosuppression and activate anti-tumor immunity, paving the way for successful cancer treatment.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Probiotics in microbiome ecological balance providing a therapeutic window against cancer

Nirmala Sehrawat et al.

Summary: The composition of the gut microbiota is crucial for maintaining human health, with prebiotics and probiotics playing a key role in balancing the microbial population. Imbalance in the microbiota can lead to dysbiosis, which is seen in cancer patients. Utilizing probiotics can help manage cancer by maintaining a healthy microbiota and inhibiting cancer progression, highlighting the potential for personalized medicine and therapeutic targets in microbiome research.

SEMINARS IN CANCER BIOLOGY (2021)

添加到收藏夹

Review Chemistry, Medicinal

Reinvigorating exhausted CD8+cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy

Md Amir Hossain et al.

Summary: Immunotherapy has revolutionized cancer treatment in recent years, but many patients still exhibit limited responses to treatment strategies. Much attention is being given to targeting exhausted CD8(+)T cells to develop new immunotherapeutic approaches. Intrinsic and extrinsic mechanisms governing CD8(+)T-cell exhaustion are being explored to overcome limitations in treatment.

MEDICINAL RESEARCH REVIEWS (2021)

添加到收藏夹

Article Engineering, Biomedical

Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma

Changrong Wang et al.

Summary: The combination of RNA interference and immunogenic chemotherapy shows potent antitumor immunity against melanoma. Using cationic polymer-lipid hybrid nanovesicles as a delivery system, the strategy induces immunogenic cell death and enhances antitumor immune responses effectively.

BIOMATERIALS (2021)

添加到收藏夹

Article Oncology

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Yuanyuan Zhang et al.

Summary: The study indicates that high levels of baseline CXCL13(+) T cells are associated with effective responses to combination therapy in triple-negative breast cancer patients. These cells increase following combination therapy but decrease after monotherapy, highlighting their importance in predicting treatment outcomes.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids

Vivien Koh et al.

Summary: The study shows that PD-L1 expression in gastric cancer is mediated by Hh and mTOR signaling pathways. Patient-derived organoid/immune cell co-cultures can be used to study immunosuppressive MDSC function. DSP analysis reveals infiltration of immunosuppressive MDSCs in gastric cancer tissues.

CANCER LETTERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment

Khiem C. Lam et al.

Summary: This study reveals how the microbiota influences the immune components of the TME to improve cancer therapy. Modulating the microbiota can trigger the IFN-I-NK cell-DC axis within tumors, enhancing the efficacy of immune checkpoint blockade (ICB).

CELL (2021)

添加到收藏夹

Article Oncology

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio et al.

Summary: The IMpower132 study demonstrated significant improvement in PFS with APP compared to PP, but the difference in OS between the two groups was not statistically significant. APP showed favorable OS and PFS results across subgroups, with a manageable safety profile and no new or unexpected safety signals identified.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer

Antonio Passaro et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

Sadna Budhu et al.

Summary: The study showed that targeting PS with antibodies can enhance the efficacy of tumor-directed RT and improve overall survival, while also increasing proinflammatory tumor-associated macrophages. Combining PD-1 blockade with RT further increases anti-tumor efficacy and survival, particularly in patients with metastatic melanoma.

CELL REPORTS (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1

Hui Li et al.

Summary: The study comprehensively characterizes immune features in cancer patients and reveals positive correlations between Sunitinib targets, immune checkpoints, and suppressive immune cells. It shows that Sunitinib enhances antitumor immunity by regulating PD-L1 stability via p62, leading to a synergistic effect with CTLA-4. Clinical observations support the combination treatment strategy for NSCLC patients.

ADVANCED SCIENCE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling

Christophe Glorieux et al.

Summary: K-ras mutations enhance PD-L1 expression through a redox-mediated mechanism, while inhibition of the FGFR1 pathway reduces PD-L1 expression and enhances T cell-mediated tumor suppression.

REDOX BIOLOGY (2021)

添加到收藏夹

Article Oncology

PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B

Shangyun Lu et al.

Summary: This study demonstrated the positive regulation of MET phosphorylation by PD-L1 as a downstream pathway, providing a novel mechanistic explanation for the tumor-intrinsic function of PD-L1. Inhibition of PD-L1 led to reduced MET phosphorylation and cell proliferation, suggesting a potential rationale for the combination of immunotherapy and MET-targeted therapy in cancer treatment.

CANCER SCIENCE (2021)

添加到收藏夹

Article Oncology

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

Hussein A. Tawbi et al.

Summary: The study demonstrated the durable response, overall survival, and progression-free survival rates for asymptomatic patients treated with nivolumab plus ipilimumab. In contrast, the efficacy was lower in symptomatic patients. Treatment-related adverse events were mainly mild to moderate.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Mutant clones in normal epithelium outcompete and eliminate emerging tumours

B. Colom et al.

Summary: Research suggests that mutant clones in normal adult tissues compete with early-formed neoplasms, helping to eliminate them through cell competition and preserve tissue integrity.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian et al.

Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Julie Westerlin Kjeldsen et al.

Summary: The IO102/IO103 vaccine targeting IDO/PD-L1, combined with nivolumab, showed favorable safety and clinical efficacy in treating metastatic melanoma, with an 80% objective response rate and 43% complete responses. This immunomodulatory approach warrants further validation in larger randomized trials to confirm its clinical potential.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer

Clemens Hinterleitner et al.

Summary: This study demonstrates that platelet-derived PD-L1 can serve as a prognostic and predictive biomarker in non-small cell lung cancer patients, playing a role in tumor immune evasion and affecting T cell function. An algorithm was developed to calculate the adjusted PD-L1 payload of platelets (pPD-L1(Adj.)), which showed superior predictive ability for therapy response compared to standard histological PD-L1 quantification.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade

Shuguang Zuo et al.

Summary: The engineering of oncolytic vaccinia virus (VV) with immune checkpoint blockade, such as VV-scFv-TIGIT, demonstrated enhanced antitumor efficacy by reshaping the suppressive tumor microenvironment and synergizing with PD-1 or LAG-3 blockade to achieve complete response in tumors with poor response to VV or immune checkpoint blockade monotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids

Qingda Meng et al.

Summary: This study reports a platform for expanding tumor-targeting T cells from the peripheral blood of patients with pancreatic cancer, and identifies the NKG2A-HLA-E axis as an important checkpoint for CD8+ T cells in pancreatic cancer. Empirical identification of tumor-targeting TCRs suitable for TCR therapy was demonstrated.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids

Jayati Chakrabarti et al.

Summary: The co-expression of HER2 and PD-L1 may contribute to immune evasion in gastric cancer. Autologous organoid/immune cell co-cultures can be utilized to screen responses to a combination of anti-HER2 and immunotherapy, guiding personalized treatment for gastric cancer patients.

CANCERS (2021)

添加到收藏夹

Article Engineering, Biomedical

Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy

Kewen Lei et al.

Summary: The study demonstrates that cancer cells enriched in cholesterol inhibit T-cell-mediated cytotoxicity, while stiffening cancer cells through cholesterol depletion enhances T-cell cytotoxicity, thereby improving the efficacy of adoptive T-cell therapy. This enhancement is attributed to increased T-cell forces at the immunological synapse, rather than influencing other T-cell functions like receptor signaling or production of cytolytic proteins. These findings suggest a mechanical immune checkpoint that could be targeted for improving cancer immunotherapies.

NATURE BIOMEDICAL ENGINEERING (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma

Lei Guo et al.

Summary: The study investigated the efficacy and mechanism of combined treatment with curcumin and anti-PD-1 in HCC, revealing synergistic anti-cancer effects in both in vitro and in vivo models.

LIFE SCIENCES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Energy status dictates PD-L1 protein abundance and anti-tumor to enable blockade

Xiaoming Dai et al.

Summary: The ketogenic diet-induced changes in energy status were found to enhance the efficacy of anti-CTLA-4 immunotherapy through various mechanisms, such as decreasing PD-L1 protein levels and increasing expression of IFNs and antigen presentation genes. AMPK activation plays a crucial role in these mechanisms, highlighting its importance in regulating the immune response to immune checkpoint blockade.

MOLECULAR CELL (2021)

添加到收藏夹

Article Oncology

Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

Zowi R. Huinen et al.

Summary: Anti-angiogenic therapy has the potential to enhance antitumor immunity by inhibiting immunosuppressive features of angiogenesis. Combinations of anti-angiogenic agents and immunotherapy have shown success in clinical trials and have been approved by the FDA. The article discusses the impact of angiogenesis on antitumor immunity, the role of endothelial cells, and the progress in combining anti-angiogenic agents with immune checkpoint inhibitors.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

Evan W. Weber et al.

Summary: This study showed that transient cessation of chimeric antigen receptor (CAR) signaling can enhance the efficacy of CAR-T cells, reactivating their anti-tumor functions, and challenging the notion that exhaustion is an epigenetically fixed state.

SCIENCE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression

Hong Zhang et al.

Summary: This study reveals the mechanism by which alcohol induces PD-L1 expression through ALDH2, facilitating immune evasion and tumor progression in colorectal cancer cells.

ADVANCED SCIENCE (2021)

添加到收藏夹

Article Oncology

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+T cells in deficient mismatch repair colorectal cancer

Qiaoqi Sui et al.

Summary: DKK1 suppresses the antitumor immune reaction via the GSK3 beta/E2F1/T-bet axis in CD8+ T cells. Elevated serum DKK1 predicts poor tumor response to PD-1 blockade in dMMR/MSI CRCs, and DKK1 neutralization may restore sensitivity to PD-1 blockade.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study

Lu Cao et al.

Summary: In cholangiocarcinoma patients, specific immune checkpoints and immune modulators are associated with poor prognosis, potentially serving as novel therapeutic targets.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy

Shangqin Sun et al.

Summary: The study evaluated the predictive performance of transcriptomic biomarkers to immune response. The immune-checkpoint biomarkers and immune effector biomarker presented predictive ability in melanoma, urothelial cancer, and clear cell renal-cell cancer. Interestingly, top-performing response biomarkers were usually mutually exclusive in patients with different ICB therapies.

CANCERS (2021)

添加到收藏夹

Review Oncology

The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development

Sandra Majo et al.

Summary: This study explores the role of collagens in the tumor microenvironment, as well as the different functions of DDRs in various cancers. It also discusses the complexity of anti-DDR therapies in cancer treatment, as well as the key factors in tumor development and metastasis.

CANCERS (2021)

添加到收藏夹

Review Oncology

Patient-Derived Cancer Organoids as Predictors of Treatment Response

Maikel Verduin et al.

Summary: Patient-derived cancer organoids are valuable tools in predicting individualized treatment responses, comparing treatment efficacies, and screening new anti-cancer drugs. However, further improvements are needed to fully utilize the potential of cancer organoids in clinical cancer therapy management.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy

Yupeng Wang et al.

Summary: An engineered biomimetic nano-RBC system utilizing hemoglobin is developed to deliver chemotherapy drugs and oxygen, effectively reprogramming the tumor immunosuppressive microenvironment. This strategy targets tumor-associated macrophages and alleviates tumor hypoxia, enhancing the antitumor immune response and inhibiting tumor metastasis and recurrence.

ADVANCED MATERIALS (2021)

添加到收藏夹

Article Oncology

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

D. Miles et al.

Summary: Combining atezolizumab with paclitaxel did not improve PFS or OS in PD-L1-positive aTNBC patients, although it showed some advantage in unconfirmed best overall response rate and duration of response.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Yujue Wang et al.

Summary: Rationally sequencing and combining PD-1/L1 and MAPK-targeted therapies may overcome innate and acquired resistance. Comparative analysis of different treatment regimens can optimize therapeutic efficacy for melanoma and colorectal and pancreatic carcinoma.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion

Yan Lan et al.

Summary: The combination of BA fusion protein with radiotherapy shows superior survival in murine tumor models, increasing tumor-infiltrating leukocytes, reprogramming the tumor microenvironment, and attenuating RT-induced fibrosis. This combination has the potential to eradicate therapy-resistant tumors while sparing normal tissue, supporting its clinical translation.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu et al.

Summary: This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy. These findings suggest a new regulatory mechanism for PD-L1 involving mRNA epigenetic modification by ALKBH5, as well as a potential role for ALKBH5 in cancer immunotherapies.

CANCER RESEARCH (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy

Kazuhiro Koikawa et al.

Summary: Upregulation of Pin1 in PDAC contributes to the desmoplastic and immunosuppressive TME, but targeting Pin1 with available drugs can synergize with immunotherapy and gemcitabine to induce complete elimination of PDAC.

CELL (2021)

添加到收藏夹

Article Oncology

Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

Corey C. Foster et al.

Summary: The study evaluated the safety and efficacy of SBRT combined with different immunotherapy drugs for advanced solid tumors, finding that SBRT combined with nivolumab+urelumab or nivolumab+cabiralizumab for treating 4 or fewer metastases is feasible with modest antitumor activity.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

添加到收藏夹

Review Oncology

Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis

Xiaoxiang Zhou et al.

Summary: This study comprehensively investigated the incidences and profiles of treatment-related adverse events in different PD-1 or PD-L1 inhibitor-based combination therapies. Results showed variations in the incidence and profiles of adverse events among different combination therapies, providing essential reference for clinicians in routine practice of cancer care.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Benjamin C. Creelan et al.

Summary: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) in combination with nivolumab showed potential safety and clinical activity in patients with advanced non-small cell lung cancer, indicating a promising new treatment strategy for metastatic lung cancer.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways

Zhen Xiang et al.

Summary: The study identified dexamethasone as a potential compound that can suppress T cell exhaustion by decreasing the activity of PD-L1 and IDO1 immune checkpoints, thus increasing sensitivity to immune checkpoint inhibitors. This finding highlights the critical role of dexamethasone in regulating tumor immune evasion.

ONCOGENE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy

Janna Krueger et al.

Summary: The study found that the use of HCQ alone or in combination with AZ reduced the therapeutic benefit of anti-PD-1 in cancer immunotherapy without causing harm to untreated tumors. Mechanistically, HCQ inhibited PD-L1 expression on tumor cells and the increase in TILs induced by anti-PD-1 treatment.

PLOS ONE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Developmental chromatin programs determine oncogenic competence in melanoma

Arianna Baggiolini et al.

Summary: The intrinsic transcriptional program present in the cell of origin plays a key role in the transforming ability of oncogenes like BRAF(V600E), with developmental chromatin factors mediating oncogenic competence and allowing for proper response to oncogenes.

SCIENCE (2021)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Opposing roles of the immune system in tumors

Won Jin Ho et al.

SCIENCE (2021)

添加到收藏夹

Article Cell Biology

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Amaia Martinez-Usatorre et al.

Summary: In the treatment of nonsmall cell lung cancer, antiangiogenic therapy can slow tumor progression, but unlike in other cancers, the addition of PD-1 or PD-L1 antibodies does not provide benefits. Antiangiogenic treatment facilitates tumor infiltration by PD-1(+) T-regs, but targeting both tumor-associated macrophages types can improve treatment efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Cecile Geuijen et al.

Summary: Researchers have discovered a human CD137xPD-L1 bispecific antibody, MCLA-145, which potently activates T cells at sub-nanomolar concentrations and demonstrates low systemic toxicity in non-human primates. The conditional activation of CD137 signaling by MCLA-145 may provide both safety and potency advantages, enhancing anti-cancer activity.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling

Hye Kyung Hong et al.

Summary: Patient-derived organotypic tumor spheroids (PDOTS) are a novel ex vivo system that retains key features of the native tumor immune microenvironment. The PDOTS model may represent an advantageous ex vivo system for developing effective immune therapeutics.

CANCER MEDICINE (2021)

添加到收藏夹

Article Oncology

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer The Phase 2 KEYNOTE-799 Nonrandomized Trial

Salma K. Jabbour et al.

Summary: The study suggests promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer

Si-Yu Wu et al.

Summary: This study identified two distinct microenvironment phenotypes, 'inflamed' and 'non-inflamed', within the classic basal-like subtype of TNBC, and revealed that MYC amplification and overexpression led to the formation of the non-inflamed TIME. Combination therapy with a DNA methyltransferase inhibitor and immunotherapy reversed T cell exhaustion and improved T cell function, resulting in potent antitumor activity in MYC-overexpressing TNBC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer

Yaohui Gao et al.

Summary: The research found that high levels of F. nucleatum are associated with improved therapeutic responses to PD-1 blockade in patients with CRC, and F. nucleatum also enhances the antitumor effects of PD-L1 blockade on CRC. Furthermore, F. nucleatum induces PD-L1 expression and increases the accumulation of interferon-gamma (IFN-gamma)(+) CD8(+) tumor-infiltrating lymphocytes.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Oncology

Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial

Aparna R. Parikh et al.

Summary: The study suggests that combining radiation with immune checkpoint blockade may have some efficacy in treating MSS colorectal cancer and pancreatic cancer, demonstrating the feasibility of this approach. It also found that higher numbers of natural killer cells and repetitive RNA transcription are correlated with disease control in patients.

NATURE CANCER (2021)

添加到收藏夹

Article Oncology

Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer

Yi Ban et al.

Summary: Research suggests that a specific dose of radiation therapy in combination with immune checkpoint inhibitors can lead to tumor regression and improved survival in non-small cell lung cancer models by activating lung-resident secretory club cells. This combination therapy enhances antitumor immune responses by inhibiting immunosuppressive myeloid cells and reducing pro-tumor inflammation. Notably, the presence of specific club cell secretory proteins in NSCLC patients responding to the combination therapy suggests a promising potential for future clinical trials.

NATURE CANCER (2021)

添加到收藏夹

Review Oncology

Targeting the DNA damage response in immuno-oncology: developments and opportunities

Roman M. Chabanon et al.

Summary: Immunotherapy has greatly improved cancer treatment outcomes, but many patients still do not benefit from it, partly due to DDR deficiency. DDR-targeted therapies can enhance antitumor immune response by promoting antigenicity, enhancing adjuvanticity, and favoring reactogenicity.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy

Eleni Panagioti et al.

Summary: This study found that combination NAP-immunovirotherapy induced massive influx of lymphoid cells in mouse brain, with CD8+ T cell predominance; therapeutic efficacy was CD8+ T cell dependent. Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Oncology

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Haiping Jiang et al.

Summary: IBI323, a dual blockade bispecific antibody targeting PD-L1 and LAG-3, showed superior immune stimulatory activity compared to each parent antibody in mouse models and demonstrated stronger anti-tumor activity against PD-L1/LAG-3 double knock-in mice bearing human PD-L1 knock-in tumors.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

A snapshot of the PD-1/PD-L1 pathway

Chinmoy Ghosh et al.

Summary: Immune checkpoint blockade is a promising strategy for treating cancer by reactivating anti-tumor immunity, but the response rates and resistance towards current anti-PD-1/PD-L1 therapies remain challenges. New perspectives are needed to overcome these hurdles for successful cancer treatment.

JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

Changxin Wan et al.

Summary: This study demonstrates that the efficacy of immune therapies in high-grade serous ovarian cancer is driven by inducing state changes in NK cells and specific subsets of T cells. The results suggest that immune therapies, such as BRD1 inhibitors, capable of inducing such cellular state changes may have increased effectiveness in treating HGSC.

CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype for updates and increased immunogenicity

Chengming Liu et al.

CANCER LETTERS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals

Elliot A. Philips et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

添加到收藏夹

Article Oncology

Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

Haifang Wang et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model

Rebecca A. Luchtel et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Article Cell Biology

High-dose vitamin C enhances cancer immunotherapy

Alessandro Magri et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Oncology

The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer

John Kwon et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular mechanism of SHP2 activation by PD-1 stimulation

M. Marasco et al.

SCIENCE ADVANCES (2020)

添加到收藏夹

Article Oncology

Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression

Man-Chin Chen et al.

CANCERS (2020)

添加到收藏夹

Review Oncology

Acquired Resistance to Immune Checkpoint Inhibitors

Adam J. Schoenfeld et al.

CANCER CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study

Giovanni Lo Re et al.

CYTOKINE (2020)

添加到收藏夹

Article Biology

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy

Alok Kumar et al.

ELIFE (2020)

添加到收藏夹

Article Cell Biology

Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases

Lin Zhang et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Immunology

The Role of PD-1 in Acute and Chronic Infection

Jil M. Jubel et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Oncology

Master protocols in immuno-oncology: do novel drugs deserve novel designs?

Luca Mazzarella et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Characterization of human cancer xenografts in humanized mice

Jonathan Rios-Doria et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells

Rudi Mao et al.

CANCER SCIENCE (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Multistage Sensitive NanoCRISPR Enable Efficient Intracellular Disruption of Immune Checkpoints for Robust Innate and Adaptive Immune Coactivation

Ning Wang et al.

ADVANCED FUNCTIONAL MATERIALS (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1

Suxing Jin et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)

添加到收藏夹

Article Oncology

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz-Ares et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Adham S. Bear et al.

CANCER CELL (2020)

添加到收藏夹

Article Oncology

Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion

Florida Voli et al.

CANCER RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Fasting-mimicking diet and hormone therapy induce breast cancer regression

Irene Caffa et al.

NATURE (2020)

添加到收藏夹

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Review Immunology

Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition

Hye-Jung Kim et al.

TRENDS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Toll-Like Receptor 9 Agonists in Cancer

Lilit Karapetyan et al.

ONCOTARGETS AND THERAPY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity

Xizi Jiang et al.

CELL AND BIOSCIENCE (2020)

添加到收藏夹

Article Oncology

Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma

Loryn Holokai et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Physical Plasma-Treated Skin Cancer Cells Amplify Tumor Cytotoxicity of Human Natural Killer (NK) Cells

Ramona Clemen et al.

CANCERS (2020)

添加到收藏夹

Editorial Material Oncology

Educational attainment in displaced children with cancer Comment

Carlene Wilson et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

Takaaki Oba et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Medicine, Research & Experimental

Vitamin C: A stem cell promoter in cancer metastasis and immunotherapy

Jingwen Fu et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

添加到收藏夹

Review Oncology

Immunotherapy as sensitizer for local radiotherapy

Ben G. L. Vanneste et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo

Qibin Liao et al.

BIOMARKER RESEARCH (2020)

添加到收藏夹

Article Medicine, General & Internal

Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab

Ramy M. Hanna et al.

SAGE OPEN MEDICAL CASE REPORTS (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy

Qianmei Yang et al.

THERANOSTICS (2020)

添加到收藏夹

Article Oncology

eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer

Shruthy Suresh et al.

NATURE CANCER (2020)

添加到收藏夹

Article Oncology

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export

Fang-Fang Chen et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Serotonin and human cancer: A critical view

Denis Sarrouilhe et al.

BIOCHIMIE (2019)

添加到收藏夹

Article Immunology

Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells

Xiaoqing Zhang et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2019)

添加到收藏夹

Article Immunology

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer

Bo Gong et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

添加到收藏夹

Article Oncology

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC

Fabrice Barlesi et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Hyun Tae Lee et al.

MOLECULES (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Neoantigen-directed immune escape in lung cancer evolution

Rachel Rosenthal et al.

NATURE (2019)

添加到收藏夹

Article Oncology

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Triparna Sen et al.

CANCER DISCOVERY (2019)

添加到收藏夹

Article Microbiology

Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection

Loryn Holokai et al.

PLOS PATHOGENS (2019)

添加到收藏夹

Review Oncology

PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis

Jing Li et al.

FUTURE ONCOLOGY (2019)

添加到收藏夹

Review Immunology

Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis

Andrew M. Frederickson et al.

IMMUNOTHERAPY (2019)

添加到收藏夹

Article Immunology

FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway

Piao Li et al.

JOURNAL OF IMMUNOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Development of the Inhibitors That Target the PD-1/PD-L1 InteractionA Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Katarzyna Guzik et al.

MOLECULES (2019)

添加到收藏夹

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

Alfredo Addeo et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy

Davide Ciardiello et al.

CANCER TREATMENT REVIEWS (2019)

添加到收藏夹

Article Oncology

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

Carminia Maria Della Corte et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Chemistry, Medicinal

Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract

Kiichiro Teruya et al.

MARINE DRUGS (2019)

添加到收藏夹

Article Oncology

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

Willemijn S. M. E. Theelen et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Nanoscience & Nanotechnology

Vitamin C Loaded Poly(urethane-urea)/ZnA-LDH Aligned Scaffolds Increase Proliferation of Corneal Keratocytes and Up-Regulate Vimentin Secretion

Mojgan Moghanizadeh-Ashkezari et al.

ACS APPLIED MATERIALS & INTERFACES (2019)

添加到收藏夹

Article Engineering, Biomedical

Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer

Bin Liu et al.

ACTA BIOMATERIALIA (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy

Jiajing Cai et al.

ONCOTARGETS AND THERAPY (2019)

添加到收藏夹

Review Immunology

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

Weiting Qin et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment

Manni Wang et al.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)

添加到收藏夹

Article Oncology

Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma

Hailong Ma et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

Jianfeng Shen et al.

CANCER RESEARCH (2019)

添加到收藏夹

Editorial Material Immunology

The brain-immune cells axis controls tissue specific immunopathology

Maxi Heyner et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells

Wenyi Gu et al.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2019)

添加到收藏夹

Article Oncology

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade

Hong Jae Chon et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Immunology

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1

Emma Eriksson et al.

JOURNAL OF IMMUNOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Xianjie Jiang et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy

Gang Shi et al.

MOLECULAR THERAPY (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Jerome Galon et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Review Cell Biology

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

Xiaobo Li et al.

CELLS (2019)

添加到收藏夹

Article Respiratory System

The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer

Yang Zhang et al.

RESPIRATORY RESEARCH (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

Li Jiang et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Oncology

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

E. E. Vokes et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Correction Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)

J. B. A. G. Haanen et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

Chia-Wei Li et al.

CANCER CELL (2018)

添加到收藏夹

Article Oncology

NFATc1 Promotes Antitumoral Effector Functions and Memory CD8(+) T-cell Differentiation during Non-Small Cell Lung Cancer Development

Lisanne Heim et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Cell Biology

EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells

Yang Wang et al.

CELL CYCLE (2018)

添加到收藏夹

Review Immunology

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

Shetal A. Patel et al.

IMMUNITY (2018)

添加到收藏夹

Article Oncology

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

John A. Thompson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

添加到收藏夹

Article Oncology

Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels

Lijun Xu et al.

MOLECULAR ONCOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Nikolaos Zacharakis et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Medicine, General & Internal

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A. Postow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution

Mirjana Efremova et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article Oncology

Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors

Cancer Discovery (2018)

添加到收藏夹

Article Oncology

Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes

Konrad Gabrusiewicz et al.

ONCOIMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Yiwen Li et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment

Samuel F. Bakhoum et al.

CELL (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Role of hypoxia-induced exosomes in tumor biology

Chuchu Shao et al.

MOLECULAR CANCER (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

Jong-Ho Cha et al.

MOLECULAR CELL (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth

Anchalee Rawangkan et al.

MOLECULES (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Gang Chen et al.

NATURE (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Sarwish Rafiq et al.

NATURE BIOTECHNOLOGY (2018)

添加到收藏夹

Review Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Spencer C. Wei et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Organoid Modeling of the Tumor Immune Microenvironment

James T. Neal et al.

CELL (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Application of atomic force microscopy in cancer research

Xiangying Deng et al.

JOURNAL OF NANOBIOTECHNOLOGY (2018)

添加到收藏夹

Article Oncology

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

George Fromm et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Immunology

Tumor immune evasion arises through loss of TNF sensitivity

Conor J. Kearney et al.

SCIENCE IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors

Ee Lyn Lim et al.

JCI INSIGHT (2018)

添加到收藏夹

Article Oncology

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients

Marie-Nicole Theodoraki et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

High Expression of lncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis

Hao Bo et al.

JOURNAL OF CANCER (2018)

添加到收藏夹

Article Oncology

BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM

Fang Wei et al.

BRITISH JOURNAL OF CANCER (2018)

添加到收藏夹

Article Oncology

Cross-talk between TNF-alpha and IFN-gamma signaling in induction of B7-H1 expression in hepatocellular carcinoma cells

Na Li et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Review Cell Biology

Organoids: A historical perspective of thinking in three dimensions

Marina Simian et al.

JOURNAL OF CELL BIOLOGY (2017)

添加到收藏夹

Article Immunology

Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory

Alexander P. R. Bally et al.

JOURNAL OF IMMUNOLOGY (2017)

添加到收藏夹

Review Immunology

Immunotherapy of cancers comes of age

Hila Yousefi et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)

添加到收藏夹

Article Immunology

Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells

Xun Wang et al.

IMMUNOLOGY LETTERS (2017)

添加到收藏夹

Meeting Abstract Oncology

Analysis of Immune Correlates Using Anti-PD-1 Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy

S. Kim et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)

添加到收藏夹

Editorial Material Medicine, General & Internal

Targeting Immune Checkpoints in Cancer Therapy

Suzanne L. Topalian

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

MicroRNA-155 induction via TNF- and IFN- suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells

Daniel Yee et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2017)

添加到收藏夹

Review Oncology

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

Bingshan Liu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer

Xiaomei Gong et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis

Tim Wartewig et al.

NATURE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Effective combinatorial immunotherapy for castration-resistant prostate cancer

Xin Lu et al.

NATURE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

cGAS surveillance of micronuclei links genome instability to innate immunity

Karen J. Mackenzie et al.

NATURE (2017)

添加到收藏夹

Review Multidisciplinary Sciences

Elements of cancer immunity and the cancer-immune set point

Daniel S. Chen et al.

NATURE (2017)

添加到收藏夹

Article Neurosciences

PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1

Gang Chen et al.

NATURE NEUROSCIENCE (2017)

添加到收藏夹

Review Oncology

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Mizuki Nishino et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer

J. Wang et al.

ONCOGENE (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

Krzysztof M. Zak et al.

STRUCTURE (2017)

添加到收藏夹

Article Oncology

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Scott Gettinger et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway

Ming Jing Shen et al.

ONCOTARGET (2017)

添加到收藏夹

Article

The role of exosomal non-coding RNAs in cancer metastasis

Jin-Peng Wang et al.

Oncotarget (2017)

添加到收藏夹

Article Cell Biology

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Angel Garcia-Diaz et al.

CELL REPORTS (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells

Fang Zheng et al.

BIOMED RESEARCH INTERNATIONAL (2017)

添加到收藏夹

Review Oncology

Role of tumor microenvironment in tumorigenesis

Maonan Wang et al.

JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade

Howard Y. Li et al.

CANCER IMMUNOLOGY RESEARCH (2017)

添加到收藏夹

Article Oncology

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Jun Zhou et al.

CANCER IMMUNOLOGY RESEARCH (2017)

添加到收藏夹

Review Oncology

Intratumoral immunotherapy: using the tumor as the remedy

A. Marabelle et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Immunology

Tumor-derived exosomes modulate PD-L1 expression in monocytes

Franziska Haderk et al.

SCIENCE IMMUNOLOGY (2017)

添加到收藏夹

Article Oncology

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Jennifer H. Yearley et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Immunology

Inflammatory cytokines compromise programmed cell death-1(PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1

D. Bommarito et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)

添加到收藏夹

Article Oncology

Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Kiyonori Tanoue et al.

CANCER RESEARCH (2017)

添加到收藏夹

Review Immunology

Immunogenic cell death in cancer and infectious disease

Lorenzo Galluzzi et al.

NATURE REVIEWS IMMUNOLOGY (2017)

添加到收藏夹

Article Oncology

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

S. Champiat et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer

Kristin J. Lastwika et al.

CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Deubiquitination and Stabilization of PD-L1 by CSN5

Seung-Oe Lim et al.

CANCER CELL (2016)

添加到收藏夹

Article Oncology

Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy

Panpan Zhang et al.

CANCER SCIENCE (2016)

添加到收藏夹

Review Oncology

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Thomas K. Eigentler et al.

CANCER TREATMENT REVIEWS (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer

Weimin Wang et al.

CELL (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Jianjun Gao et al.

CELL (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

Andy J. Minn et al.

CELL (2016)

添加到收藏夹

Editorial Material Cell Biology

MYC - a thorn in the side of cancer immunity

Stefani Spranger et al.

CELL RESEARCH (2016)

添加到收藏夹

Article Oncology

Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

Masaki Mandai et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Immunology

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion

Bertram Bengsch et al.

IMMUNITY (2016)

添加到收藏夹

Review Immunology

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

Jonathan M. Pitt et al.

IMMUNITY (2016)

添加到收藏夹

Article Oncology

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

Nan Zhang et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher et al.

LANCET (2016)

添加到收藏夹

Article Oncology

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Biotechnology & Applied Microbiology

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

Tessa Gargett et al.

MOLECULAR THERAPY (2016)

添加到收藏夹

Article Medicine, General & Internal

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Eric Tran et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Jonathan T. Sockolosky et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

添加到收藏夹

Review Respiratory System

Immunotherapy for lung cancer

Antonius Steven et al.

RESPIROLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

MYC regulates the antitumor immune response through CD47 and PD-L1

Stephanie C. Casey et al.

SCIENCE (2016)

添加到收藏夹

Article Cell Biology

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

Dimitrios Mathios et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

添加到收藏夹

Article Immunology

Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial

Joanna E. Long et al.

VACCINE (2016)

添加到收藏夹

Review Immunology

The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation

Kankana Bardhan et al.

FRONTIERS IN IMMUNOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers

Hidetoshi Sumimoto et al.

PLOS ONE (2016)

添加到收藏夹

Review Oncology

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Lorenzo Galluzzi et al.

CANCER CELL (2015)

添加到收藏夹

Review Oncology

Targeting immune checkpoints: New opportunity for mesothelioma treatment?

Elly Marcq et al.

CANCER TREATMENT REVIEWS (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Sonja Kleffel et al.

CELL (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

Santiago Zelenay et al.

CELL (2015)

添加到收藏夹

Article Cell Biology

Extracellular vesicles shuffling intercellular messages: for good or for bad

Alessandra Lo Cicero et al.

CURRENT OPINION IN CELL BIOLOGY (2015)

添加到收藏夹

Article Dermatology

The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma

Natalie Spaccarelli et al.

DERMATOLOGIC CLINICS (2015)

添加到收藏夹

Editorial Material Urology & Nephrology

Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Timothy J. Daskivich et al.

EUROPEAN UROLOGY (2015)

添加到收藏夹

Article Oncology

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells

Sanja Stevanovic et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Biochemical Research Methods

Human PD-1 binds differently to its human ligands: A comprehensive modeling study

Clement Viricel et al.

JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2015)

添加到收藏夹

Article Oncology

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma

Ahmad A. Tarhini et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Oncolytic viruses: a new class of immunotherapy drugs

Howard L. Kaufman et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

Roy L. Maute et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

Erika Vacchelli et al.

SCIENCE (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

New immunotherapies targeting the PD-1 pathway

Jordan M. Chinai et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2015)

添加到收藏夹

Article Oncology

Several immune escape patterns in non-Hodgkin's lymphomas

Camille Laurent et al.

ONCOIMMUNOLOGY (2015)

添加到收藏夹

Editorial Material Oncology

Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?

Guido Kroemer et al.

ONCOIMMUNOLOGY (2015)

添加到收藏夹

Review Physiology

The role of serotonin and its receptors in activation of immune responses and inflammation

M. S. Shajib et al.

ACTA PHYSIOLOGICA (2015)

添加到收藏夹

Article Immunology

PD-1 induction through TCR activation is partially regulated by endogenous TGF-β

Raja Rekik et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

Nicolas J. Llosa et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Article Oncology

PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients

Shenyou Sun et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Programmed death ligand-1 expression in non-small cell lung cancer

Vamsidhar Velcheti et al.

LABORATORY INVESTIGATION (2014)

添加到收藏夹

Article Oncology

Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients

Andreas Pircher et al.

LUNG CANCER (2014)

添加到收藏夹

Article Multidisciplinary Sciences

PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells

Hatem Soliman et al.

PLOS ONE (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer

Eric Tran et al.

SCIENCE (2014)

添加到收藏夹

Article Oncology

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

S. Muenst et al.

BREAST CANCER RESEARCH AND TREATMENT (2013)

添加到收藏夹

Article Oncology

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

Xiaofeng Jiang et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Oncology

Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung

Jennifer M. Boland et al.

CLINICAL LUNG CANCER (2013)

添加到收藏夹

Review Immunology

Oncology Meets Immunology: The Cancer-Immunity Cycle

Daniel S. Chen et al.

IMMUNITY (2013)

添加到收藏夹

Article Neurosciences

PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients

Yawei Liu et al.

JOURNAL OF NEUROSCIENCE (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

Nikolaos Patsoukis et al.

MOLECULAR AND CELLULAR BIOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

Minmin Song et al.

PLOS ONE (2013)

添加到收藏夹

Article Cell Biology

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

Stefani Spranger et al.

SCIENCE TRANSLATIONAL MEDICINE (2013)

添加到收藏夹

Article Oncology

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Esra A. Akbay et al.

CANCER DISCOVERY (2013)

添加到收藏夹

Review Surgery

Role of the PD-1 Pathway in the Immune Response

L. V. Riella et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

MYC on the Path to Cancer

Chi V. Dang

CELL (2012)

添加到收藏夹

Article Medicine, General & Internal

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Oncology

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Steven A. Rosenberg et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion

Kimberly A. Hofmeyer et al.

JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)

添加到收藏夹

Article Immunology

IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

Seigo Terawaki et al.

JOURNAL OF IMMUNOLOGY (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

PD-L2 is expressed on activated human T cells and regulates their function

Nassima Messal et al.

MOLECULAR IMMUNOLOGY (2011)

添加到收藏夹

Review Immunology

T cell exhaustion

E. John Wherry

NATURE IMMUNOLOGY (2011)

添加到收藏夹

Article Oncology

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

Julie Vincent et al.

CANCER RESEARCH (2010)

添加到收藏夹

Review Immunology

The PD-1 pathway in tolerance and autoimmunity

Loise M. Francisco et al.

IMMUNOLOGICAL REVIEWS (2010)

添加到收藏夹

Article Immunology

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Kaori Sakuishi et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

Elias A. Said et al.

NATURE MEDICINE (2010)

添加到收藏夹

Article Hematology

PD-1 on dendritic cells impedes innate immunity against bacterial infection

Sheng Yao et al.

BLOOD (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

Siddhartha Jaiswal et al.

CELL (2009)

添加到收藏夹

Article Immunology

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Loise M. Francisco et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

添加到收藏夹

Article Endocrinology & Metabolism

Human Prostate-Infiltrating CD8+ T Lymphocytes are Oligoclonal and PD-I+

Karen S. Sfanos et al.

PROSTATE (2009)

添加到收藏夹

Review Immunology

PD-1 and its ligands in tolerance and immunity

Mary E. Keir et al.

ANNUAL REVIEW OF IMMUNOLOGY (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

Interferon-sensitive response element (ISRE) is mainly responsible for IFN-α-induced upregulation of programmed death-1 (PD-1) in macrophages

Hae-Yun Cho et al.

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2008)

添加到收藏夹

Article Hematology

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Takeshi Azuma et al.

BLOOD (2008)

添加到收藏夹

Review Immunology

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

Lionel Apetoh et al.

IMMUNOLOGICAL REVIEWS (2007)

添加到收藏夹

Article Hematology

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy

Fumihiko Tsushima et al.

BLOOD (2007)

添加到收藏夹

Review Immunology

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

Arlene H. Sharpe et al.

NATURE IMMUNOLOGY (2007)

添加到收藏夹

Article Cell Biology

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

Hadi Valadi et al.

NATURE CELL BIOLOGY (2007)

添加到收藏夹

Article Multidisciplinary Sciences

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Jerom Galon et al.

SCIENCE (2006)

添加到收藏夹

Article Multidisciplinary Sciences

Regulation of T cell activation and tolerance by PDL2

Yongliang Zhang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

添加到收藏夹

Article Oncology

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up

RH Thompson et al.

CANCER RESEARCH (2006)

添加到收藏夹

Article Multidisciplinary Sciences

Restoring function in exhausted CD8 T cells during chronic viral infection

DL Barber et al.

NATURE (2006)

添加到收藏夹

Article Multidisciplinary Sciences

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

E Sato et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

添加到收藏夹

Article Immunology

PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion

PA Saunders et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2005)

添加到收藏夹

Article Immunology

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

Y Iwai et al.

INTERNATIONAL IMMUNOLOGY (2005)

添加到收藏夹

Article Immunology

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

JM Chemnitz et al.

JOURNAL OF IMMUNOLOGY (2004)

添加到收藏夹

Article Immunology

B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism

XL Liu et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2003)

添加到收藏夹

Article Multidisciplinary Sciences

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

FS Hodi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

添加到收藏夹

Article Immunology

B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy

N Selenko-Gebauer et al.

JOURNAL OF IMMUNOLOGY (2003)

添加到收藏夹

Review Immunology

The PI-3 kinase/Akt pathway and T cell activation:: pleiotropic pathways downstream of PIP3

LP Kane et al.

IMMUNOLOGICAL REVIEWS (2003)

添加到收藏夹

Article Immunology

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

SY Tseng et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2001)

添加到收藏夹

Article Immunology

PD-L2 is a second ligand for PD-I and inhibits T cell activation

Y Latchman et al.

NATURE IMMUNOLOGY (2001)

添加到收藏夹

Article Immunology

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

GJ Freeman et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2000)

添加到收藏夹

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

相关参考文献